Group3 medulloblastoma (MB G3 ) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MB G3 models are currently lacking, making inferences related to their cellular origin thus far limited. Using in utero electroporation, we here report that MB G3 mouse models can be developed in situ from different multipotent embryonic cerebellar progenitor cells via conditional expression of Myc and loss of Trp53 function in several Cre driver mouse lines. The Blbp-Cre driver that targets embryonic neural progenitors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventricle, recapitulating human MB G3 . Enforced co-expression of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic neuronal progenitors as well as cerebellar granule cells give rise to MB G3 with their distinct growth kinetics. Cross-species gene expression analysis revealed that these novel MB G3 models shared molecular characteristics with human MB G3 , irrespective of their cellular origin. We here developed MB G3 mouse models in their physiological environment and we show that oncogenic insults drive this MB subgroup in different cerebellar lineages rather than in a specific cell of origin.
INTRODUCTION
Medulloblastoma (MB), a malignant embryonal brain tumor with a peak incidence in childhood, exhibits considerable molecular heterogeneity with the existence of at least four distinct subgroups-Wingless (WNT), Sonic Hedgehog (SHH), Group3 (G3) and Group4 (G4). 1, 2 These subgroups have distinct characteristics with respect to age, gender, prognosis and response to therapy. 3 The genetic and phenotypic differences of MB subgroups are in part attributable to differences in their cellular origin. 4 Identification of the cellular origin of a tumor often relies on the molecular characterization of normal and tumor tissues; however, tumor-specific somatic alterations likely confound such analysis. Thus, the generation of genetically engineered animals bearing tumors arisen under physiological conditions provides a context for investigating oncogenic events underlying the transformation of a normal cell into a tumor cell in vivo.
Spatial and temporal specification of cell fate within the cerebellum is well characterized, 5 and has been integral to the identification of molecular signatures associated with cerebellar neuronal subtypes along the spectrum of neurogenesis. 6 These neuronal lineages provide a means to assess the effect of genetic modifications (e.g. activation of oncogenes and deletion of tumor suppressor genes) on a specific neuronal sub-population, and thus to develop genetically engineered MB mouse models. 7 A number of studies have uncovered distinct cells of origin for MB subgroups: genetic ablation of Ptch1 enables descendants of cerebellar stem cells (e.g. granule neuron precursors (GNPs) and Nestin-positive ( + ) cells) to form SHH MBs (MB SHH ), [8] [9] [10] whereas expression of a constitutively active mutant form of Ctnnb1 in dorsal hindbrain progenitors, generates WNT MBs (MB WNT ). 11 In contrast, forced activation of WNT signaling in GNPs impairs their proliferation and induces differentiation, [12] [13] [14] which highlights the differences in cancer susceptibility among neural progenitors under the influence of the same oncogenic insult. Enforced expression of MYCN under the glutamate transporter 1 (Glt1) promoter or in neonatal cells positive for the glial fibrillary acidic protein (GFAP + ) induces MBs with high expression of Kcna1, a known marker of G4 MBs (MB G4 ), 15 whereas MYCN overexpression in Trp53-null GNPs or embryonic cerebellar stem cells triggers MB SHH . [15] [16] [17] These studies demonstrate that genetic insults to specific cerebellar cell types can influence the subgroup-specific characteristics of MBs.
MYC-driven MBs are mainly classified as G3 (MB G3 ) and represent one of the most aggressive subgroup. 2, 3 They are characterized by frequent metastasis at diagnosis and are often associated with a dismal outcome. 18 So far, several orthotopic models of MYC-driven MB G3 were developed in mice by Myc and Trp53 dysregulation. 12, 16, 19 We and another group independently reported the first orthotopic mouse model of MB G3 by overexpressing Myc in combination with functional loss of Trp53 in postnatal cerebellar cells selected by fluorescence-activated cell sorting for the basic helix-loop-helix transcription factor Atoh1-positive (Atoh1   +   ) and Prominin/CD133-positive (Prom1 + ) cells. 12, 16 Nevertheless, while human MB G3 have been found in relatively young children, 20 the role of Myc expression in transforming embryonic stem/progenitors into malignant cells under physiological conditions has not yet been tested. We here report the first MB G3 model from embryonic cerebellar cells by Myc activation and loss of Trp53 function using in utero electroporation (EP)-based in vivo gene transfer combined to a MYC-driven medulloblastoma from embryonic progenitors D Kawauchi et al
Cre/LoxP-mediated technology. The present study also provides the opportunity to trace tumor growth with bioluminescence and fluorescent proteins, which will help in the future to not only understand cellular and molecular mechanisms of tumorigenesis but also to undertake further preclinical trials.
RESULTS

EP of embryonic cerebellar neuroepithelium with Myc and
Trp53DN induces MB G3 Human MB G3 is typically restricted to infants and younger children, 20 prompting us to assess the predisposition of embryonic cerebellar progenitors to initiate MB G3 . Previous orthotopic MB G3 models from postnatal progenitors required loss of Trp53 function to overcome cell death caused by excess Myc expression. 12 Consistent with these results, the oncogenic transcriptional repressor growth factor independent 1, known to antagonize Trp53, 21 was subsequently shown to cooperate with Myc to induce MB G3 in an orthotopic transplant model. 22 Indeed, MYC-TP53 dysfunction has been reported in relapsed human MB G3 . 23 We reasoned that we could use Myc expression and a dominant-negative form of Trp53 to model MB G3 using embryonic cells. In vivo EP of plasmids into mouse embryos is an effective method to transfer genes into cerebellar progenitors under physiological conditions. 11, 24 To avoid dilution of plasmid-driven gene expression as cells divide, we used the Tol2 transposonmediated genomic integration system. 25 We constructed two Tol2 cis-flanked CAG promoter-driven plasmids: Tol2-CAG-LoxP-DsRed2-LoxP (LRL)-Myc-IRES-Luciferase (Luc)-Tol2 (pT2K LRL-Myc-IRES-Luc) that strongly express both Myc and Luc after excision of the LRL cassette in the presence of the Cre recombinase protein (Figures 1a and b) and Tol2-CAG-Trp53DN-copGFP-Tol2, encoding a dominant-negative form of Trp53 (Trp53DN) 26 fused to a T2A peptide with arthropod-derived green fluorescent protein (copGFP) (pT2K Trp53DN-copGFP). To target broadly cerebellar neural stem/progenitor cells, as the first step these plasmids were electroporated into brain lipid-binding protein (Blbp)-Cre-IRESnuclear localized LacZ (nlacZ) embryos at embryonic (E) day 13.5 together with the Tol2 transposase (T2TP)-carrying plasmid (pCAGGS T2TP) that lacks Tol2 cis elements to prevent multiple gene 'hopping' (Figure 1c) . At E13.5, Cre expression was restricted to the cerebellar ventricular zone (VZ) and the external granule layer (EGL), the two germinal zones of the cerebellum (Supplementary Figures 1a and b′ Figures 1f-h) . We electroporated the LRL-EGFP gene 27 into the cerebellar neuroepithelium of [Blbp-Cre-IRES-nlacZ] embryos by EP at E13.5 to confirm that Cre-mediated recombination of transfected plasmids occurred in vivo. Two days after EP (E15.5), most of the labeled cells expressed enhanced green fluorescent protein (EGFP) rather than DsRed2 ( Supplementary  Figures 1i and j) , which is consistent with the distribution of Cre + cells revealed by X-gal staining (Supplementary Figure 1k) . We also observed a small population of EGFP + cells in the choroid plexus (CP) (Supplementary Figure 1j) Figures 1l-n) .
We next performed in utero EP of LRL-Myc-IRES-Luc and T2TP with or without Trp53DN-copGFP in [Blbp-Cre-IRES-nlacZ] embryos at E13.5 and subsequently monitored Luc activation in neonatal mice by in vivo bioluminescence. Strong Luc signal was detected in the head of Cre-carrying, but not wild-type (Cre-negative) mice (Figure 1d ). In the absence of Trp53DN-copGFP, the bioluminescence signal disappeared by 5 weeks after birth and no MBs developed within 5 months after birth (n = 6, Supplementary Table 1 ). All the other tumors were diagnosed as MBs with large-cell anaplastic characteristics (hereafter called Blbp-MYC MB) (Figures 1e-h ). Tumors were highly proliferative (Ki67 + ) with MB G3 characteristics, namely Npr3 expression (Figures 1i and j) . Importantly, tumor cells strongly expressed copGFP (Figure 1k ), indicating that Trp53 inactivation is a prerequisite of MB G3 formation. EP-induced Blbp-MYC MBs also showed strong expression of known stem cell marker genes (Figure 1l ). These tumors displayed gene expression profiles for the most part different from Myc-driven CPCs; however, some genes were shared with MB G3 (e.g. Figures 4c-f ). The lesions were immunoreactive for Atoh1 (Figures 3o-q″) , a marker of proliferating GNPs, 5 but not Tbr2 (Figures 3r-t″) , a marker for unipolar blush cells in the developing cerebellum. 29 Deep cerebellar nuclear neurons, which are also cerebellar excitatory neurons, are born and leave from the VZ at an earlier time point (E10.5-12.5) than when EP was performed (E13.5). 29 Furthermore, EP in the cerebella of Atoh1-Cre mice developed copGFP + hyperproliferative clusters in neonatal mice ( Supplementary Figures 4g and h) . Consistent with the results of GNP-derived Atoh1ER-MYC orthotopic models described below, GNPs are most likely responsible for the development of hyperplastic lesions in this EP-based model. Figures 1h and n) . Nevertheless, they might not allow proper evaluation of the possibility that Myc overexpression and loss of Trp53 function could transform committed inhibitory interneuron progenitors due to rapid growth of MB G3 from GNPs. We therefore used pancreas specific transcription factor 1a [(Ptf1a) In utero electroporation at E13.5. Figure 5o) . 11 Unlike Blbp-MYC and Atoh1-MYC MBs, the bioluminescence signal intensity from transfected [Gad2-IRES-Cre] and [Ptf1a-Cre] mice gradually decayed during the first several weeks after birth, but subsequently showed a marked increase in intensity with mice succumbing to tumor burden between 9 and 14 weeks after birth (Figures 4a, c and d ; hereafter called Gad2-MYC and Ptf1a-MYC MBs). Intriguingly, peak of Luc signals were detected in several brain regions in mice from both models (Figures 4c and d) , implying multifocal tumor development. Histopathological analysis revealed that Ptf1a-MYC and Gad2-MYC MBs, as well as one Atoh1-MYC MB have a large-cell anaplastic MB phenotype and high expression of Npr3 (Figures 4e-j) . Interestingly, hyperproliferative lesions were not found in the cerebella of EP-induced Myc-driven MBs molecularly recapitulate human MB G3 Using different Cre drivers, we generated EP-based MB G3 models from different cell types (Table 1) . We compared gene expression profiles of these tumors with orthotopic Myc-driven MB G3 models engineered from postnatal cerebellar progenitors. We here developed [Atoh1-CreER; Trp53
MYC-driven
Fl/− ] and [Prom1-CreER; Trp53 Fl/− ] mice that lacked one allele of Trp53 in the germline. Mouse pups were administered tamoxifen at P0 and P1 to genetically delete ) and G3 location was distinct from SHH (P = 0.0005) and WNT (P = 0.008), but not G4 (P = 0.63). (e-g) Heat map of Blbp-MYC MB tumors (n = 6). Tumors were outlined on representative H&E-stained sections (e and f) and overlayed on a parasagittal plane at x = 0.12 mm (g) from the Franklin and Paxino brain atlas. 28 Coordinates units are mm relative to Bregma, and color indicates cumulative number of tumors. The rostral-caudal orientation of the atlas slice is reversed for comparison with the human atlas. (h-m) Representative MRI imaging of 4-year-old human MB G3 patient (h-j) and 57-day-old mouse bearing a tumor (k-m). Colored dots highlight points for comparison of the anatomic similarity of tumor localization that was apparent in 2/6 Blbp-MYC MB studied with MRI. Figure 6 ). Cerebellar cells were purified by percoll density gradient centrifugation, infected in vitro with retroviruses carrying Myc and red fluorescent protein and transplanted into the cortices of naive recipient nude mice as reported previously. 16 Tumors from Atoh1-CreER + and Prom1-CreER + cells (hereafter referred to as 
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Atoh1ER-MYC and Prom1ER-MYC MBs, respectively) developed within 3 months after birth (Supplementary Figure 7) . These tumors as well as our previous model 16 exhibited large-cell anaplastic characteristics and high expression of Npr3, a faithful marker of MB G3 (Supplementary Figure 7) . 2 Unsupervised hierarchical clustering using the top 1000 signature genes from the 430 v.2 Affymetix microarray chip (Affymetrix, Santa Clara, CA, USA) revealed that EP-based MB G3 and orthotopic MB G3 tumors clustered separately from each other and from published murine MB WNT and MB SHH models (Figure 5a ). Consistent with these results, principal component analysis using all genes measured on the arrays revealed that the MB G3 models reported here group together, were similar to our previous orthotopic models 16 and were clearly separated from MB WNT and MB SHH models (Figure 5b ). Of note, EP-MYC tumors did not form subclustering in a cellular origin-dependent manner (Supplementary Figure 8a) . Rather, they were intermingled with each other, suggesting that dysfunction of MYC and TP53 is a strong determinant driving MB G3 , overriding their origins. Consistent with this idea, cross-species analysis using orthologs for mouse MB models. Bars represent aggregated prediction probabilities that each mouse model belongs to each MB subgroup, as determined by a random forest classifier that was trained on expression barcodes of human and mouse MB samples. The probabilities that Ptf1a-MYC tumors belong to MB G4 are not significantly higher than Blbp-MYC MBs (P = 0.90, n = 9, Wilcoxon's rank-sum test). Similarly, Gad2-MYC tumors do not have significantly higher probabilities of belonging to MB G4 compared to Blbp-MYC MBs (P-value = 0.48, n = 10).
between human and mouse further revealed significant similarity of EP-mediated tumors to human MB G3 (Figure 5c and Supplementary Figures 8b-d) . Irrespective of the cell types examined in this study, EP-based tumors generated by aberrant activation of Myc combined with the loss of Trp53 function mimicked human MB G3 .
DISCUSSION
Identifying the cellular origin of solid tumors is of utmost importance to better understand the transformation of a normal cell into a cancer cell, especially regarding the lineage dependency driving tumor subtype diversity. The in utero EP-based gene transfer system enabled us to examine the susceptibility of distinct cerebellar progenitors to transformation by Myc overexpression and Trp53 loss into malignant MB G3 . Hyperplasia formation in [Blbp-Cre] and [Atoh1-Cre] mice at neonatal stages clearly indicated that cerebellar cellular transformation began during embryogenesis. The expression of Atoh1 but not Sox2 within the hyperplastic cells suggests a commitment of neural stem cells to GNPs before transformation ensues. In addition, the lack of hyperplasia in electroporated [Ptf1a-Cre] and [Gad2-Cre] neonatal cerebella, as well as incomplete penetrance of MB G3 from these animals, implies resistance of inhibitory interneuron progenitors to Myc-induced transformation. Thus, our study suggests that there are critical periods during which distinct neuronal progenitors are susceptible to hyperproliferation and/or transformation in response to the same oncogenic insults.
Tumor localization within the caudal cerebellum of Blbp-Cre animals was consistent with our measurements of human MB G3 tumors around the caudal midline of the fourth ventricle in tight clusters as well as with subgroup-specific categorical descriptions of human MBs based on diagnostic MRI studies. 31, 32 We previously showed that quantitative tumor localization within the posterior fossa reflects the molecular and cellular context of tumorigenesis for MB WNT and MB SHH in both mice and human. 11 The distribution of human MB G3 tumors suggests that tumors arise from the caudal vermis, which develops from the medial cerebellar primordium in human 33 and mouse, 34 and postnatal lateral-to-medial migration of postmitotic EGL granule cells that populates the expanding caudal vermis, at least in the mouse. 34 Convergence toward the midline of granule cells from an extended segment of the upper rhombic lip might afford opportunities for transformation of MYCinduced cells and help to explain the low variability of MB G3 tumors location in humans.
Our Last, this study validated that our approach would be a feasible and versatile method to evaluate roles of oncogene in different cell lineages. We also recently developed EP-based SHH-driven MBs and GBMs by induction of CRISPR/Cas9-mediated somatic mutations. 37 Furthermore, we also developed in vivo chronic labeling of CRISPR/Cas9-targeted cells with GFP using conditional Cas9-GFP knock-in animals. 38 These EP technologies will further foster the generation of new brain tumor models for preclinical studies and will increase our understanding of the cellular and molecular mechanisms of brain tumor development. ]. 39 Cre-carrying male were bred with CD-1 female mice (Charles River, Wilmington, MA, USA) for in utero EP. Day E0.5 was defined by the observation of a vaginal plug and the day of birth as P0. Conditional deletion of the Trp53 gene was performed by administration of tamoxifen (Sigma, St Louis, MO, USA) at P0 and P1 (4 mg/ 40 g body weight). All experiments were conducted in strict accordance with the National Institute of Health guidelines for the Care and Use of Laboratory Animals and according to the guidelines established by the SJCRH Institutional Animal Care and Use Committee. All procedures in the protocol were approved by the Animal Care and Use Committee (ACUC) of SJCRH (Animal Assurance Number: A3077-01) and were approved by the responsible authorities in Germany (G176/13 and G48/14).
MATERIALS AND METHODS
Animal husbandry
Plasmids and virus production
For Tol2 transposon-mediated stable expression, we used pCAGGS T2TP and pT2K LRL-EGFP. 25 EGFP of pT2K LRL-EGFP was replaced with either IRESluc or Myc-IRES-luc, yielding pT2K LRL-IRES-luc and pT2K LRL-Myc-IRES-luc, respectively. The gene encoding Trp53DN 26 was fused to the T2A peptide with copGFP (Trp53DN-copGFP) and was inserted into the pT2K-CAGGS plasmid, yielding pT2K Trp53DN-copGFP. Retroviruses were produced as described previously. 16 Generation of mouse MB G3 models To develop EP-based MB G3 models, in utero EP was performed. 37 Only the animals showing luciferase signal by P7 were selected for further analysis. Tumor growth was measured every 1-2 week by bioluminescence imaging of luciferase activity using a Xenogen IVIS system (PerkinElmer, Waltham, MA, USA). 41 Orthotopic MB G3 mouse models were generated by cranial implants of purified GNPs from [Trp53 ] P6-7 pups, infected with retroviruses carrying Myc and red fluorescent protein according to the previous study. 16 No specific randomization or blinding was performed. Tumor cell purification and genomic DNA and total RNA extraction for genotyping and Affymetrix microarray analysis were described previously. 16 For detection of non-recombined and recombined alleles of Trp53 in Atoh1ER-MYC and Prom1ER-MYC MBs, 1F/1R (370 bp) and 1F/10R (612 bp) primer sets were used, respectively. 42 For internal control, endogenous Prom1 (563 bp) 43 and Ptch1 (220 bp) 17 were detected. Comparison of survival curves was performed by calculation of twotailed P-value using the GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). 
Gene expression analysis
Human Affymetrix U133 plus 2.0 expression array data for genes of interest were extracted from publicly available data sets (GSE10327, GSE12992, GSE37418 and GSE49243) 40, [44] [45] [46] from the R2 software tool for analysis and visualization of genomic data (http://r2.amc.nl) (Amsterdam, The Netherlands). Additional cases came from an unpublished data set generated at the DKFZ (Heidelberg, Germany) (M Kool et al., unpublished data). Total RNAs from murine tumors were extracted and analyzed with the Affymetrix 430 v.2 chip. The microarray data of murine SHH and WNT spontaneous medulloblastoma, 11, 39 as well as some of the orthotopic MB G3 models were retrieved from our previous study. 16 RNA from four CPC and one MB G3 mouse tumors were extracted and analyzed by mogene 2.0 ST arrays where the MB G3 RNA was a repeated measure of a pre-existing 430 v.2 array. Data were RMA normalized in Partek Genomics Suite 6.6 (St Louis, MO, USA) and imported in STATA/MP 14.2 (StataCorp LLC, College Station, TX, USA) in which unannotated and duplicated probe sets were removed such that only the highest measured probe sets was retained for any gene. The mouse 430 v.2 array data was also deduplicated in the same manner for MB SHH and MB G3 data. These two data sets were then joined by gene symbol and a chip-based correction for each gene was calculated by finding the simple difference in RMA signal in the 430 v.2 sample that matched the mogene 2.0 ST Grp3 sample. Finally, the mogene 2.0 samples data were corrected using this factor and the resulting matrix was principal component analysis visualized. Further selected matched genes were clustered and displayed in a heat map using Partek Genomics Suite 6.6.
Antibodies
All antibodies used in this study are shown in Supplementary Table 1.
Immunohistochemistry IHC was performed with the antibodies shown in Supplementary Table 2 according to the previous study. 16 For quantification of the stained sections (five sections per brain), the number of positive (+) markers (for example, Ki67 and GFP + cells) in the most posterior lobules (IX and X) were counted and used to calculate the ratio of positive marker (for example, Ki67 
Immunoblotting
Mycoplasma-free HEK293T cells from American Type Culture Collection (Manassas, VA, USA) were transfected with pT2K-empty (negative control), pT2K Myc-IRES-Luc (positive control), and pT2K LRL-Myc-IRES-Luc with or without MSCV-Cre plasmids and harvested 2 days after transfection. Protein lysates were prepared from the transfected HEK293T cells using standard RIPA buffer (Sigma) and used 10 μg of the lysates for immunoblotting.
Neurosphere culture and differentiation assay Cerebellar cells from postnatal (P) day P7 [Prom1-CreER; R26-LSL-EYFP] mice treated with tamoxifen at P0 and P1 were purified as published previously, 16 followed by fluorescence-activated cell sorting sorting of EYFP expressing cells. Sorted cells were plated in serum-free Neurobasal media supplemented with B27 and N2 (Invitrogen, Carlsbad, CA, USA) (passage 0). Basic fibroblast growth factor (50 ng/ml; Peprotech, Rocky Hill, NJ, USA) and epidermal growth factor (EGF) (50 ng/ml; Peprotech) were added every 3 days and neurospheres were passaged every 7-10 days. After the second passage, cells were dissociated with trypsin and subsequently plated on Matrigel-coated coverslips. For differentiation assays, basic fibroblast growth factor and EGF were removed and platelet-derived growth factor-AA (10 ng/ml; Sigma) was added for 2 weeks. Cultured cells were fixed with 4% paraformaldehyde/ phosphate-buffered saline, followed by immunofluorescence.
MRI imaging
In patients, preoperative imaging was acquired at the local hospital where each patient had tumor resection before referral for protocol-based therapy at SJCRH, and analyzed, as reported previously. 11 The research protocol was approved by the SJCRH Institutional Review Board and all patients gave written informed consent to participate. The preoperative imaging examination varied among patients, but always included T1-weighted scans before and after administration of a gadolinium-based contrast agent. The slice thickness was 4 or 5 mm and the in-plane resolution was 0.8 to 1 mm. T1-weighted images from all patients were wrapped, or spatially normalized, 47 to the standard brain space defined by the Montreal Neurological Institute (MNI) brain template. 48, 49 The MNI space approximates the proportional stereotaxic brain space of Talairach and Tournoux, 50 which was extended to the cerebellum in the atlas by Schmahmann et al. 51 Spatial normalization was performed with Statistical Parametric Mapping software (SPM5; Wellcome Institute of Neurology, London, UK) using default parameters, except that the brain bounding box was extended from 50 to 80 mm in the negative z-direction for sagittal images and all output images were resliced to 1 mm x 1 mm x 1 mm resolution. The T1-weighted images without contrast agent were used for spatial normalization because the tumor contrast was low, which would minimize adverse effects of the tumor on the accuracy of spatial normalization. To characterize the accuracy of spatial normalization we defined a set of landmarks from the MNI space that were identified in the normalized images from each patient. The landmarks and their MNI coordinates (x, y, z) included the center of the anterior commissure (0, 5, − 4), the cerebral aqueduct (0, − 30, − 10), a point on the posterior aspect of the brain stem in the fourth ventricle (0, − 34, − 26), the apex of the cerebellum in the midline (0, − 54, 4) and lateral extremes of the cerebellum on the right (59, − 58, − 39) and left (−59, − 58, − 39). 51 The locations of landmarks in the normalized images of each patient were measured with the 3D Slicer software (version 3.4, http://www.slicer.org). 52 Cross-species analysis
To classify mouse models molecularly, all analyses were performed in the R environment (v.3.1.2) with CRAN and Bioconductor (v.3.0) packages, including GEOquery (v.2.32), frma (v.1.18), sva (v.3.12), randomForest (v.4.6) and ggplot2 (v.1.0). Public expression data of human MBs were collated from previous studies. 40, 45, 46, 53, 54 Raw expression data of human MBs on the Affymetrix Human Genome U133 Plus 2.0 array platform (Affymetrix) were retrieved from GEO accessions GSE10327, GSE12992, GSE19404, GSE35493 and GSE37418. This data set was integrated with an expression data set (on the Affymetrix Mouse 430 2.0 array platform) of previously published mouse models of MB WNT , MB SHH and MB G3 (accessions GSE33199 and GSE24628) 11, 16 in addition to expression data of mouse models generated in the current study. The raw data was normalized using fRMA, 55 transformed into z-scores using Barcode, 56 adjusted for center-specific biases and cross-species differences using ComBat, and converted into expression barcodes (non-expressed vs expressed) with a logarithm (base 10) of odds score threshold of 12. The human samples and the mouse samples of previously published models were used to train a random forest classifier. 56 The expression barcodes of the data sets were visualized by principal component analysis. The integrated data set (expression barcodes) of human MBs and previously published mouse MB models was used to train a random forest classifier. 57 For computational efficiency, genes determined to be non-expressed across all samples were removed before training. The trained classifier was subsequently used to predict the molecular subgroups (WNT, SHH, G3, G4) of each mouse tumor sample in the present study by its expression barcode. For each sample, the distribution of votes across the classes was interpreted as the posterior probability distribution of the sample belonging to each class. The posterior probability of a mouse model belonging to class, given the expression data of samples of the model, was calculated as 
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All microarray data has been submitted to the US National Institute of Health GEO database under the accession numbers GSE65888 and GSE33199.
